ARTICLE | Company News
Bolder BioTechnology, National Institutes of Health autoimmune news
September 3, 2007 7:00 AM UTC
Bolder received a $685,984 Phase II SBIR grant from NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases to conduct preclinical studies of a pegylated VEGF receptor in disease m...